<a target="_blank" href="https://www.buzzsprout.com/twilio/text_messages/1035190/open_sms">Reach us by sending a text</a>

<a href="https://www.buzzsprout.com/twilio/text_messages/1035190/open_sms" rel="noopener noreferrer">Reach us by sending a text</a>

Ep. 23 - $21B Deal by Gilead, None by PhRMA

BioCentury's streaming commentary on biotech industry trends, plus interviews with KOLs. For three decades, BioCentury has helped biopharma executives and investors make business-critical decisions and build larger networks with peers across the innovation ecosystem.

Business

Science

Life Sciences

BioCentury's streaming commentary on biotech industry trends, plus interviews with KOLs. For three decades, BioCentury has helped biopharma executives and investors make business-critical decisions and build larger networks with peers across the innovation ecosystem.

Share Ep. 23 - $21B Deal by Gilead, None by PhRMA

Sign up to save your podcasts

Ep. 23 - $21B Deal by Gilead, None by PhRMA

Ep. 23 - $21B Deal by Gilead, None by PhRMA

More shows like BioCentury This Week

Freakonomics Radio

Bloomberg Intelligence

Odd Lots

Nature Podcast

The Long Run with Luke Timmerman

The Readout Loud

Making Sense

Thoughts on the Market

Biotech 2050 Podcast

Business Of Biotech

MIT Technology Review Narrated

Biotech Hangout

WSJ's Take On the Week

The Top Line

The BioCentury Show